Smith & Nephew Gynecology (Truclear)
→
Medtronic
Acquisition · Cash · MDT · announced May 18, 2016
Announced
May 18, 2016
Closed
Aug 8, 2016
Economics
Cash()
Pre-deal · pre-deal mark: 2016, year precision · Medtronic 8-K filing, SEC EDGAR — Truclear acquisition
$350M divestiture price (Smith & Nephew press release)
Target
Smith & Nephew Gynecology (Truclear)
Gynecological Surgery · Clinical / therapeutic
HQ London, UK
TRUCLEAR hysteroscopic tissue resection system for minimally invasive treatment of abnormal uterine bleeding — polyps and fibroids; $56M annual revenue at divestiture
- Smith & Nephew press release (May 18, 2016)
- Medtronic press release (May 18, 2016)
- MassDevice deal coverage (Aug 8, 2016 — close confirmed)
Acquirer
Medtronic (MDT)
Gynecological Surgery
HQ Dublin, Ireland
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
TRUCLEAR hysteroscopic system expands minimally invasive GYN portfolio — targets abnormal uterine bleeding (polyps/fibroids) with $56M trailing revenue
Evidence ladder
Secondary (press / IR)
Medtronic press release (May 18, 2016)
Secondary (press / IR)
Smith & Nephew press release (Aug 8, 2016 — close confirmation)
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- $350M divestiture price (Smith & Nephew press release)
- Pre-deal valuation sourced from: Medtronic 8-K filing, SEC EDGAR — Truclear acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Gynecological Surgery
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
Insufficient disclosed data
No verified Gynecological Surgery deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.
Other verified deals by Medtronic
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by Medtronic are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Smith & Nephew Gynecology (Truclear) (Gynecological Surgery). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.